Pathogenesis, Therapeutic Targets, and Drug Development for Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH)
Metabolic dysfunction-associated steatohepatitis is jointly driven by hepatic fat accumulation, lipotoxicity, insulin resistance, inflammation, and fibrosis. Targeting lipid metabolism, nuclear receptors, incretin pathways, and FGF signaling has become a major direction in drug development.
危险品化学品经营许可证(带存储)